otibiovin
bioveta, Česká republilka - sol.
trichoben av
bioveta, Česká republilka - inj.sicc.
biocan novel respi
bioveta, Česká republilka - susp.
sarclisa
sanofi winthrop industrie - isatuximab - viacnásobný myelóm - antineoplastické činidlá - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.
fosrenol 250 mg žuvacie tablety
shire pharmaceutical contracts ltd. - hydrát uhličitanu lantanitého - 87 - varia i
fosrenol 1000 mg žuvacie tablety
shire pharmaceutical contracts ltd. - hydrát uhličitanu lantanitého - 87 - varia i
fosrenol 1000 mg perorálny prášok
shire pharmaceutical contracts ltd. - hydrát uhličitanu lantanitého - 87 - varia i
fosrenol 750 mg perorálny prášok
shire pharmaceutical contracts ltd. - hydrát uhličitanu lantanitého - 87 - varia i
sergon 500 iu/ml prášok na prípravu injekčného roztoku s rozpúšťadlom